Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists
Citations Over TimeTop 12% of 1997 papers
Abstract
The synthesis and pharmacological evaluation of 5 (L-738, 167), a potent, selective non-peptide fibrinogen receptor antagonist is reported. Compound 5 inhibited the aggregation of human gel-filtered platelets with an IC50 value of 8 nM and was found to be > 33000-fold less effective at inhibiting the attachment of human endothelial cells to fibrinogen, fibronectin, and vitronectin than it was at inhibiting platelet aggregation. Ex vivo platelet aggregation was inhibited by > 85% 24 h after the oral administration of 5 to dogs at 100 micrograms/kg. The extended pharmacodynamic profile exhibited by 5 appears to be a consequence of its high-affinity binding to GPIIb/IIIa on circulating platelets and suggests that 5 is suitable for once-a-day dosing.
Related Papers
- → Evidence for sequential utilization of fibronectin, vitronectin, and collagen during fibroblast‐mediated collagen contraction(2002)84 cited
- → Opposing effects of collagen I and vitronectin on fibronectin fibril structure and function(2014)24 cited
- → Integrin-mediated adhesion of human mesenchymal stem cells to extracellular matrix proteins adsorbed to polymer surfaces(2012)28 cited
- → Kinetic analysis of integrin‐dependent cell adhesion on vitronectin(1998)40 cited
- → Vitronectin is significant in the adhesion of lens epithelial cells to PMMA polymers(2004)15 cited